Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1077 of 6351
-
Laser and immunotherapy combo takes on recurrent brain tumors
Disease control OngoingThe purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimen…
Phase 1/2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
A simple dye might replace radioactive tracers in cancer staging
Diagnosis CompletedThis is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with cancers and subjected to surgery. The diagnostic …
Phase 3 • Sponsor: Institut de Cancérologie de Lorraine • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Patient choice in prostate cancer: two pills, one preference
Disease control CompletedTo assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy shows promise for tough blood cancers
Disease control CompletedThe purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occ…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Shorter combo therapy shows promise for advanced melanoma
Disease control OngoingThis research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for mantle cell lymphoma: transplant combo vs drug alone in major trial
Disease control OngoingThis phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce c…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody combo shows promise against Hard-to-Treat colorectal cancer
Disease control CompletedThis randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be remove…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to keep relapsed myeloma in check
Disease control OngoingBased on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. …
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New blood test could slash unnecessary antibiotics in sick newborns
Diagnosis CompletedLate-onset neonatal sepsis (LOS), occurring in newborn of at least 7 days of life, is frequently observed in Neonatal Intensive Care Units (NICUs) and potentially severe (mortality, neurologic and respiratory impairments). Despite its high prevalence, a reliable diagnostic remai…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 26, 2026 13:26 UTC
-
Bladder cancer trial explores immunotherapy cocktails to fight recurrence
Disease control OngoingUpon successful screening and registration, enrollment to a cohort will begin. If DLT criteria are exceeded in a cohort, that cohort will close and will not proceed to Phase 2 of the study. Provided the safety of a cohort is established, enrollment will continue. Within BCG-conta…
Phase 1/2 • Sponsor: Noah Hahn, M.D. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Implant zaps bladder nerves to stop sudden leaks
Disease control CompletedThe ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed or could not tolerate more conservative treatments.
Sponsor: Axonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Personalized antibody therapy could tame deadly gut infections
Disease control Recruiting nowThe aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to 1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival. 2. Identification …
Phase 2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a numbing wash cut opioid use after breast surgery?
Symptom relief OngoingThe purpose of this study is to compare using FDA-approved bupivacaine (a numbing medicine), along with the usual medications for post-operative pain control to using the usual medications for postoperative pain control alone. The addition of bupivacaine to the surgical wound sit…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Experimental combo aims to outsmart resistant prostate cancer
Disease control CompletedThis was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer. The study was designed to determine the maximum tolerated dos…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Two-Drug attack on tough lymphoma shows promise in early trial
Disease control OngoingThis phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembro…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Weekly shot could replace daily growth hormone injections for children
Disease control CompletedA 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that wil…
Phase 3 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a dissolvable glue seal the brain and stop leaks after surgery?
Disease control CompletedThis is a multicenter, randomized, single-blind, positive-controlled, non-inferiority clinical trial designed to evaluate the safety and effectiveness of an absorbable medical adhesive (developed by Guangzhou Maipu Regenerative Medical Technology Co., Ltd.) as an adjunctive metho…
Phase 3 • Sponsor: Medprin Regenerative Medical Technologies Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Timing is everything: new study seeks best sequence for breast cancer combo therapy
Disease control OngoingGiven the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to t…
Phase 3 • Sponsor: Borstkanker Onderzoek Groep • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New chemo combo shows promise in Triple-Negative breast cancer
Disease control CompletedThis is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast cancer in neoadjuvant settings.
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC